Stoke Therapeutics (STOK) Free Cash Flow (2018 - 2026)

Stoke Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$60.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 146.23% year-over-year to -$60.9 million in Q1 2026; TTM through Mar 2026 was -$147.8 million, a 313.25% decrease from a year earlier, with the FY2025 full-year figure at $44.9 million, up 151.59% from the prior year.
• Free Cash Flow retreated to -$60.9 million in Q1 2026 per STOK's latest filing, from -$31.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $131.8 million in Q1 2025 and bottomed at -$60.9 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$21.7 million (2022), against an average of -$12.8 million.
• Across the five-year window, Free Cash Flow plunged 168.0% in 2023 and soared 636.38% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$22.1 million in 2022, then rose by 5.48% to -$20.9 million in 2023, then fell by 12.01% to -$23.4 million in 2024, then tumbled by 32.7% to -$31.0 million in 2025, then plunged by 96.36% to -$60.9 million in 2026.
• Per Business Quant, the three latest STOK Free Cash Flow figures stand at -$60.9 million (Q1 2026), -$31.0 million (Q4 2025), and -$30.4 million (Q3 2025).